Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth
来源：Reuters发布于 2026-09-08
Sandoz aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its fo...
本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。